KNApSAcK Metabolite C00004579
Metabolite
KNApSAcK Entry
| id | C00004579 |
|---|---|
| Name | Fisetin / 3,3',4',7-Tetrahydroxyflavone / 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one |
| CAS RN | 528-48-3 |
| Standard InChI | InChI=1S/C15H10O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20H |
| Standard InChI (Main Layer) | InChI=1S/C15H10O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20H |
Cluster
| Phytochemical cluster | No. 15 |
|---|---|
| KCF-S cluster | No. 71 |
Link
ChEMBL
| By standard InChI | CHEMBL31574 |
|---|---|
| By standard InChI Main Layer | CHEMBL31574 |
KEGG
| By LinkDB | C10041 |
|---|
CTD
| By CAS RN | C017875 |
|---|
Species
Summary
Plant class
| class name | count |
|---|---|
| rosids | 79 |
Family
| family name | count |
|---|---|
| Fabaceae | 76 |
| Anacardiaceae | 2 |
| Clusiaceae | 1 |
List (79)
* NCBI
Human Protein / Gene in interaction
53 ChEMBL Protein in interactions
| accession | description | class description | compound | assay ID (# of activities) |
# of diseases
(OMIM / KEGG) |
|---|---|---|---|---|---|
| P22310 | UDP-glucuronosyltransferase 1-4 | Enzyme | CHEMBL31574 |
CHEMBL1908081
(1)
CHEMBL1908082
(1)
|
3 / 0 |
| P04637 | Cellular tumor antigen p53 | Transcription Factor | CHEMBL31574 |
CHEMBL1613995
(2)
|
7 / 44 |
| Q9HAW8 | UDP-glucuronosyltransferase 1-10 | Enzyme | CHEMBL31574 |
CHEMBL1908087
(1)
|
0 / 0 |
| P29466 | Caspase-1 | C14 | CHEMBL31574 |
CHEMBL1614158
(2)
|
0 / 0 |
| Q92793 | CREB-binding protein | Enzyme | CHEMBL31574 |
CHEMBL1614040
(2)
CHEMBL1614026
(2)
|
1 / 1 |
| P02545 | Prelamin-A/C | Unclassified protein | CHEMBL31574 |
CHEMBL1614544
(1)
|
11 / 10 |
| P47989 | Xanthine dehydrogenase/oxidase | Oxidoreductase | CHEMBL31574 |
CHEMBL1023248
(1)
|
1 / 1 |
| Q00534 | Cyclin-dependent kinase 6 | CMGC serine/threonine protein kinase family | CHEMBL31574 |
CHEMBL832923
(1)
|
1 / 0 |
| P11309 | Serine/threonine-protein kinase pim-1 | Pim | CHEMBL31574 |
CHEMBL862675
(1)
CHEMBL862676
(1)
CHEMBL926333 (1) |
0 / 0 |
| P24941 | Cyclin-dependent kinase 2 | Cdc2 | CHEMBL31574 |
CHEMBL897015
(1)
|
0 / 0 |
| P11712 | Cytochrome P450 2C9 | Cytochrome P450 2C9 | CHEMBL31574 |
CHEMBL1614027
(2)
|
0 / 1 |
| Q00535 | Cyclin-dependent kinase 5 | Cdk5 | CHEMBL31574 |
CHEMBL876996
(1)
|
0 / 0 |
| Q15078 | Cyclin-dependent kinase 5 activator 1 | REG serine/threonine protein kinase family | CHEMBL31574 |
CHEMBL876996
(1)
|
0 / 0 |
| P11387 | DNA topoisomerase 1 | Isomerase | CHEMBL31574 |
CHEMBL987597
(1)
|
0 / 0 |
| P11388 | DNA topoisomerase 2-alpha | Isomerase | CHEMBL31574 |
CHEMBL1014692
(1)
CHEMBL1014697
(1)
CHEMBL987598 (1) |
0 / 0 |
| O15296 | Arachidonate 15-lipoxygenase B | Enzyme | CHEMBL31574 |
CHEMBL924097
(1)
CHEMBL1613800
(1)
|
0 / 0 |
| P00352 | Retinal dehydrogenase 1 | Enzyme | CHEMBL31574 |
CHEMBL1614458
(1)
|
0 / 0 |
| P68871 | Hemoglobin subunit beta | Secreted protein | CHEMBL31574 |
CHEMBL1613976
(1)
|
4 / 4 |
| O60656 | UDP-glucuronosyltransferase 1-9 | Enzyme | CHEMBL31574 |
CHEMBL1908086
(1)
|
0 / 0 |
| P54855 | UDP-glucuronosyltransferase 2B15 | Enzyme | CHEMBL31574 |
CHEMBL1908090
(1)
|
0 / 0 |
| P04150 | Glucocorticoid receptor | NR3C1 | CHEMBL31574 |
CHEMBL1052489
(1)
CHEMBL1052500
(1)
|
0 / 1 |
| P06276 | Cholinesterase | Hydrolase | CHEMBL31574 |
CHEMBL1045780
(1)
|
0 / 0 |
| P04745 | Alpha-amylase 1 | Enzyme | CHEMBL31574 |
CHEMBL964479
(2)
|
0 / 0 |
| P18054 | Arachidonate 12-lipoxygenase, 12S-type | Enzyme | CHEMBL31574 |
CHEMBL924094
(1)
CHEMBL1614252
(1)
|
2 / 0 |
| P28482 | Mitogen-activated protein kinase 1 | Erk | CHEMBL31574 |
CHEMBL1613808
(1)
CHEMBL1614010
(1)
|
0 / 0 |
| Q99714 | 3-hydroxyacyl-CoA dehydrogenase type-2 | Enzyme | CHEMBL31574 |
CHEMBL1613910
(2)
CHEMBL1614227
(2)
|
3 / 3 |
| Q9UNQ0 | ATP-binding cassette sub-family G member 2 | ATP binding cassette | CHEMBL31574 |
CHEMBL2076825
(1)
CHEMBL2076839
(1)
|
2 / 0 |
| P15428 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)] | Enzyme | CHEMBL31574 |
CHEMBL1614038
(2)
|
2 / 2 |
| Q9HAW9 | UDP-glucuronosyltransferase 1-8 | Enzyme | CHEMBL31574 |
CHEMBL1908085
(1)
|
0 / 0 |
| P22303 | Acetylcholinesterase | Hydrolase | CHEMBL31574 |
CHEMBL1045781
(1)
|
1 / 0 |
| Q02880 | DNA topoisomerase 2-beta | Isomerase | CHEMBL31574 |
CHEMBL687375
(1)
|
0 / 0 |
| P16050 | Arachidonate 15-lipoxygenase | Enzyme | CHEMBL31574 |
CHEMBL924095
(1)
CHEMBL924098
(1)
CHEMBL1614240 (2) |
0 / 0 |
| P55210 | Caspase-7 | C14 | CHEMBL31574 |
CHEMBL1613779
(2)
|
0 / 0 |
| P08684 | Cytochrome P450 3A4 | Cytochrome P450 3A4 | CHEMBL31574 |
CHEMBL1614108
(2)
CHEMBL1613886
(2)
|
0 / 1 |
| Q15046 | Lysine--tRNA ligase | Enzyme | CHEMBL31574 |
CHEMBL2173401
(1)
CHEMBL2173408
(1)
|
2 / 1 |
| P27695 | DNA-(apurinic or apyrimidinic site) lyase | Enzyme | CHEMBL31574 |
CHEMBL1614466
(1)
CHEMBL1614211
(2)
|
0 / 0 |
| P22309 | UDP-glucuronosyltransferase 1-1 | Enzyme | CHEMBL31574 |
CHEMBL1908080
(2)
|
5 / 1 |
| P10636 | Microtubule-associated protein tau | Unclassified protein | CHEMBL31574 |
CHEMBL1614421
(2)
CHEMBL1614502
(2)
|
4 / 3 |
| P19224 | UDP-glucuronosyltransferase 1-6 | Enzyme | CHEMBL31574 |
CHEMBL1908083
(1)
|
0 / 0 |
| P10275 | Androgen receptor | NR3C4 | CHEMBL31574 |
CHEMBL1052499
(1)
|
3 / 4 |
| P06239 | Tyrosine-protein kinase Lck | Src | CHEMBL31574 |
CHEMBL941407
(1)
|
0 / 1 |
| Q04760 | Lactoylglutathione lyase | Enzyme | CHEMBL31574 |
CHEMBL684310
(1)
|
0 / 0 |
| Q9UBT6 | DNA polymerase kappa | Enzyme | CHEMBL31574 |
CHEMBL1794536
(2)
|
0 / 0 |
| B2RXH2 | Lysine-specific demethylase 4E | Enzyme | CHEMBL31574 |
CHEMBL1613914
(1)
|
0 / 0 |
| P46063 | ATP-dependent DNA helicase Q1 | Enzyme | CHEMBL31574 |
CHEMBL1613829
(1)
|
0 / 0 |
| O00255 | Menin | Unclassified protein | CHEMBL31574 |
CHEMBL1614257
(2)
CHEMBL1614531
(2)
|
2 / 5 |
| Q03164 | Histone-lysine N-methyltransferase 2A | Enzyme | CHEMBL31574 |
CHEMBL1614257
(2)
CHEMBL1614531
(2)
|
1 / 3 |
| O95067 | G2/mitotic-specific cyclin-B2 | Other cytosolic protein | CHEMBL31574 |
CHEMBL832848
(1)
|
0 / 0 |
| P14635 | G2/mitotic-specific cyclin-B1 | Other cytosolic protein | CHEMBL31574 |
CHEMBL832848
(1)
|
0 / 0 |
| P06493 | Cyclin-dependent kinase 1 | Cdc2 | CHEMBL31574 |
CHEMBL832848
(1)
|
0 / 0 |
| Q8WWL7 | G2/mitotic-specific cyclin-B3 | Other cytosolic protein | CHEMBL31574 |
CHEMBL832848
(1)
|
0 / 0 |
| P49840 | Glycogen synthase kinase-3 alpha | Gsk | CHEMBL31574 |
CHEMBL832706
(1)
|
0 / 0 |
| P49841 | Glycogen synthase kinase-3 beta | Gsk | CHEMBL31574 |
CHEMBL832706
(1)
|
0 / 0 |
CTD interaction (73)
| compound | gene | gene name | gene description | interaction | interaction type | form |
reference
pmid |
|---|---|---|---|---|---|---|---|
| C017875 | 367 |
AR
AIS DHTR HUMARA HYSP1 KD NR3C4 SBMA SMAX1 TFM |
androgen receptor | fisetin inhibits the reaction [Dihydrotestosterone results in increased expression of AR protein] |
decreases reaction
/ increases expression |
protein |
18922931
|
| C017875 | 367 |
AR
AIS DHTR HUMARA HYSP1 KD NR3C4 SBMA SMAX1 TFM |
androgen receptor | fisetin inhibits the reaction [Metribolone results in increased folding of and results in increased stability of AR protein] |
decreases reaction
/ increases folding / increases stability |
protein |
18922931
|
| C017875 | 367 |
AR
AIS DHTR HUMARA HYSP1 KD NR3C4 SBMA SMAX1 TFM |
androgen receptor | fisetin results in decreased expression of AR mRNA |
decreases expression
|
mRNA |
18922931
|
| C017875 | 367 |
AR
AIS DHTR HUMARA HYSP1 KD NR3C4 SBMA SMAX1 TFM |
androgen receptor | fisetin results in decreased stability of and results in decreased expression of AR protein |
decreases expression
/ decreases stability |
protein |
18922931
|
| C017875 | 578 |
BAK1
BAK BAK-LIKE BCL2L7 CDN1 |
BCL2-antagonist/killer 1 | [Cisplatin co-treated with fisetin] results in increased expression of BAK1 protein |
affects cotreatment
/ increases expression |
protein |
21216935
|
| C017875 | 637 |
BID
FP497 |
BH3 interacting domain death agonist | [Cisplatin co-treated with fisetin] results in increased cleavage of BID protein |
affects cotreatment
/ increases cleavage |
protein |
21216935
|
| C017875 | 637 |
BID
FP497 |
BH3 interacting domain death agonist | fisetin results in increased cleavage of BID protein |
increases cleavage
|
protein |
21216935
|
| C017875 | 332 |
BIRC5
API4 EPR-1 |
baculoviral IAP repeat containing 5 | [Cisplatin co-treated with fisetin] results in decreased expression of BIRC5 protein |
affects cotreatment
/ decreases expression |
protein |
21216935
|
| C017875 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [fisetin results in increased activity of CASP3 protein] |
decreases reaction
/ increases activity |
protein |
21964635
|
| C017875 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | [Cisplatin co-treated with fisetin] results in increased cleavage of and results in increased activity of CASP3 protein |
affects cotreatment
/ increases activity / increases cleavage |
protein |
21216935
|
| C017875 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | fisetin inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA] |
decreases reaction
/ increases expression |
mRNA |
22931364
|
| C017875 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | fisetin results in increased activity of CASP3 protein |
increases activity
|
protein |
21964635
|
| C017875 | 840 |
CASP7
CASP-7 CMH-1 ICE-LAP3 LICE2 MCH3 |
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) | [Cisplatin co-treated with fisetin] promotes the reaction [CASP9 protein results in increased cleavage of CASP7 protein] |
affects cotreatment
/ increases cleavage / increases reaction |
protein |
21216935
|
| C017875 | 840 |
CASP7
CASP-7 CMH-1 ICE-LAP3 LICE2 MCH3 |
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) | fisetin promotes the reaction [CASP9 protein results in increased cleavage of CASP7 protein] |
increases cleavage
/ increases reaction |
protein |
21216935
|
| C017875 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [fisetin results in increased activity of CASP8 protein] |
decreases reaction
/ increases activity |
protein |
21964635
|
| C017875 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | [Cisplatin co-treated with fisetin] results in increased cleavage of and results in increased activity of CASP8 protein |
affects cotreatment
/ increases activity / increases cleavage |
protein |
21216935
|
| C017875 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | fisetin results in increased activity of CASP8 protein |
increases activity
|
protein |
21964635
|
| C017875 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | fisetin results in increased cleavage of and results in increased activity of CASP8 protein |
increases activity
/ increases cleavage |
protein |
21216935
|
| C017875 | 842 |
CASP9
APAF-3 APAF3 ICE-LAP6 MCH6 PPP1R56 |
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) | [Cisplatin co-treated with fisetin] promotes the reaction [CASP9 protein results in increased cleavage of CASP7 protein] |
affects cotreatment
/ increases cleavage / increases reaction |
protein |
21216935
|
| C017875 | 842 |
CASP9
APAF-3 APAF3 ICE-LAP6 MCH6 PPP1R56 |
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) | [Cisplatin co-treated with fisetin] results in increased cleavage of and results in increased activity of CASP9 protein |
affects cotreatment
/ increases activity / increases cleavage |
protein |
21216935
|
| C017875 | 842 |
CASP9
APAF-3 APAF3 ICE-LAP6 MCH6 PPP1R56 |
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) | fisetin promotes the reaction [CASP9 protein results in increased cleavage of CASP7 protein] |
increases cleavage
/ increases reaction |
protein |
21216935
|
| C017875 | 842 |
CASP9
APAF-3 APAF3 ICE-LAP6 MCH6 PPP1R56 |
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) | fisetin results in increased cleavage of and results in increased activity of CASP9 protein |
increases activity
/ increases cleavage |
protein |
21216935
|
| C017875 | 891 |
CCNB1
CCNB |
cyclin B1 | [Cisplatin co-treated with fisetin] results in decreased expression of CCNB1 protein |
affects cotreatment
/ decreases expression |
protein |
21216935
|
| C017875 | 891 |
CCNB1
CCNB |
cyclin B1 | fisetin results in decreased expression of CCNB1 protein |
decreases expression
|
protein |
21216935
|
| C017875 | 958 |
CD40
Bp50 CDW40 TNFRSF5 p50 |
CD40 molecule, TNF receptor superfamily member 5 | fisetin inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CD40 protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
16601352
|
| C017875 | 1026 |
CDKN1A
CAP20 CDKN1 CIP1 MDA-6 P21 SDI1 WAF1 p21CIP1 |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) | [Cisplatin co-treated with fisetin] results in increased expression of CDKN1A protein |
affects cotreatment
/ increases expression |
protein |
21216935
|
| C017875 | 1026 |
CDKN1A
CAP20 CDKN1 CIP1 MDA-6 P21 SDI1 WAF1 p21CIP1 |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) | fisetin results in increased expression of CDKN1A protein |
increases expression
|
protein |
21216935
|
| C017875 | 1312 |
COMT
|
catechol-O-methyltransferase (EC:2.1.1.6) | [fisetin co-treated with COMT protein] results in decreased activity of DNMT1 protein |
affects cotreatment
/ decreases activity |
protein |
16037419
|
| C017875 | 1734 |
DIO2
5DII D2 DIOII SelY TXDI2 |
deiodinase, iodothyronine, type II (EC:1.97.1.10) | fisetin results in increased activity of DIO2 protein |
increases activity
|
protein |
17327447
|
| C017875 | 1786 |
DNMT1
ADCADN AIM CXXC9 DNMT HSN1E MCMT |
DNA (cytosine-5-)-methyltransferase 1 (EC:2.1.1.37) | [fisetin co-treated with COMT protein] results in decreased activity of DNMT1 protein |
affects cotreatment
/ decreases activity |
protein |
16037419
|
| C017875 | 356 |
FASLG
ALPS1B APT1LG1 APTL CD178 CD95-L CD95L FASL TNFSF6 |
Fas ligand (TNF superfamily, member 6) | [Cisplatin co-treated with fisetin] results in increased expression of FASLG protein |
affects cotreatment
/ increases expression |
protein |
21216935
|
| C017875 | 356 |
FASLG
ALPS1B APT1LG1 APTL CD178 CD95-L CD95L FASL TNFSF6 |
Fas ligand (TNF superfamily, member 6) | fisetin results in increased expression of FASLG protein |
increases expression
|
protein |
21216935
|
| C017875 | 3162 |
HMOX1
HMOX1D HO-1 HSP32 bK286B10 |
heme oxygenase (decycling) 1 (EC:1.14.99.3) | fisetin results in increased expression of HMOX1 protein |
increases expression
|
protein |
16799064
|
| C017875 | 3596 |
IL13
IL-13 P600 |
interleukin 13 | fisetin inhibits the reaction [[Calcimycin co-treated with phorbol-12-myristate] results in increased expression of IL13 protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12789233
|
| C017875 | 3596 |
IL13
IL-13 P600 |
interleukin 13 | fisetin inhibits the reaction [Calcimycin results in increased expression of IL13 mRNA] |
decreases reaction
/ increases expression |
mRNA |
12789233
|
| C017875 | 3553 |
IL1B
IL-1 IL1-BETA IL1F2 |
interleukin 1, beta | fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL1B mRNA] |
affects cotreatment
/ decreases reaction / increases expression |
mRNA |
18958421
|
| C017875 | 3553 |
IL1B
IL-1 IL1-BETA IL1F2 |
interleukin 1, beta | fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased secretion of IL1B protein] |
affects cotreatment
/ decreases reaction / increases secretion |
protein |
18958421
|
| C017875 | 3565 |
IL4
BCGF-1 BCGF1 BSF-1 BSF1 IL-4 |
interleukin 4 | fisetin inhibits the reaction [[Calcimycin co-treated with phorbol-12-myristate] results in increased expression of IL4 protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12789233
|
| C017875 | 3565 |
IL4
BCGF-1 BCGF1 BSF-1 BSF1 IL-4 |
interleukin 4 | fisetin inhibits the reaction [Calcimycin results in increased expression of IL4 mRNA] |
decreases reaction
/ increases expression |
mRNA |
12789233
|
| C017875 | 3565 |
IL4
BCGF-1 BCGF1 BSF-1 BSF1 IL-4 |
interleukin 4 | fisetin results in decreased expression of IL4 protein |
decreases expression
|
protein |
16343431
|
| C017875 | 3567 |
IL5
EDF IL-5 TRF |
interleukin 5 (colony-stimulating factor, eosinophil) | fisetin inhibits the reaction [[Calcimycin co-treated with phorbol-12-myristate] results in increased expression of IL5 protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12789233
|
| C017875 | 3567 |
IL5
EDF IL-5 TRF |
interleukin 5 (colony-stimulating factor, eosinophil) | fisetin inhibits the reaction [Calcimycin results in increased expression of IL5 mRNA] |
decreases reaction
/ increases expression |
mRNA |
12789233
|
| C017875 | 3569 |
IL6
BSF2 HGF HSF IFNB2 IL-6 |
interleukin 6 (interferon, beta 2) | fisetin inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA] |
decreases reaction
/ increases expression |
mRNA |
22931364
|
| C017875 | 3569 |
IL6
BSF2 HGF HSF IFNB2 IL-6 |
interleukin 6 (interferon, beta 2) | fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 mRNA] |
affects cotreatment
/ decreases reaction / increases expression |
mRNA |
18958421
|
| C017875 | 3569 |
IL6
BSF2 HGF HSF IFNB2 IL-6 |
interleukin 6 (interferon, beta 2) | fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased secretion of IL6 protein] |
affects cotreatment
/ decreases reaction / increases secretion |
protein |
18958421
|
| C017875 | 3576 |
IL8
CXCL8 GCP-1 GCP1 LECT LUCT LYNAP MDNCF MONAP NAF NAP-1 NAP1 |
interleukin 8 | fisetin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL8 protein] |
decreases reaction
/ increases secretion |
protein |
17884996
|
| C017875 | 3576 |
IL8
CXCL8 GCP-1 GCP1 LECT LUCT LYNAP MDNCF MONAP NAF NAP-1 NAP1 |
interleukin 8 | fisetin inhibits the reaction [Silicon Dioxide results in increased expression of IL8 mRNA] |
decreases reaction
/ increases expression |
mRNA |
22931364
|
| C017875 | 3576 |
IL8
CXCL8 GCP-1 GCP1 LECT LUCT LYNAP MDNCF MONAP NAF NAP-1 NAP1 |
interleukin 8 | fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL8 mRNA] |
affects cotreatment
/ decreases reaction / increases expression |
mRNA |
18958421
|
| C017875 | 3576 |
IL8
CXCL8 GCP-1 GCP1 LECT LUCT LYNAP MDNCF MONAP NAF NAP-1 NAP1 |
interleukin 8 | fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased secretion of IL8 protein] |
affects cotreatment
/ decreases reaction / increases secretion |
protein |
18958421
|
| C017875 | 354 |
KLK3
APS KLK2A1 PSA hK3 |
kallikrein-related peptidase 3 (EC:3.4.21.77) | fisetin inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 protein] |
decreases reaction
/ increases expression |
protein |
18922931
|
| C017875 | 354 |
KLK3
APS KLK2A1 PSA hK3 |
kallikrein-related peptidase 3 (EC:3.4.21.77) | fisetin results in decreased expression of and results in decreased secretion of KLK3 protein |
decreases expression
/ decreases secretion |
protein |
18922931
|
| C017875 | 354 |
KLK3
APS KLK2A1 PSA hK3 |
kallikrein-related peptidase 3 (EC:3.4.21.77) | fisetin results in decreased expression of KLK3 mRNA |
decreases expression
|
mRNA |
18922931
|
| C017875 | 5594 |
MAPK1
ERK ERK2 ERT1 MAPK2 P42MAPK PRKM1 PRKM2 p38 p40 p41 p41mapk |
mitogen-activated protein kinase 1 (EC:2.7.11.24) | fisetin results in increased phosphorylation of MAPK1 protein |
increases phosphorylation
|
protein |
21964635
|
| C017875 | 5595 |
MAPK3
ERK-1 ERK1 ERT2 HS44KDAP HUMKER1A P44ERK1 P44MAPK PRKM3 p44-ERK1 p44-MAPK |
mitogen-activated protein kinase 3 (EC:2.7.11.24) | fisetin results in increased phosphorylation of MAPK3 protein |
increases phosphorylation
|
protein |
21964635
|
| C017875 | 4318 |
MMP9
CLG4B GELB MANDP2 MMP-9 |
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) (EC:3.4.24.35) | fisetin inhibits the reaction [Silicon Dioxide results in increased expression of MMP9 mRNA] |
decreases reaction
/ increases expression |
mRNA |
22931364
|
| C017875 | 4773 |
NFATC2
NFAT1 NFATP |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 | fisetin inhibits the reaction [Calcimycin results in increased activity of NFATC2 protein] |
decreases reaction
/ increases activity |
protein |
12789233
|
| C017875 | 4780 |
NFE2L2
NRF2 |
nuclear factor, erythroid 2-like 2 | fisetin results in increased expression of NFE2L2 protein |
increases expression
|
protein |
16799064
|
| C017875 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | fisetin results in decreased activity of PARP1 protein |
decreases activity
|
protein |
17884996
|
| C017875 | 5970 |
RELA
NFKB3 p65 |
v-rel avian reticuloendotheliosis viral oncogene homolog A | fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] affects the localization of and results in increased activity of RELA protein] |
affects cotreatment
/ affects localization / decreases reaction / increases activity |
protein |
18958421
|
| C017875 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF mRNA] |
affects cotreatment
/ decreases reaction / increases expression |
mRNA |
18958421
|
| C017875 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased secretion of TNF protein] |
affects cotreatment
/ decreases reaction / increases secretion |
protein |
18958421
|
| C017875 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | [Cisplatin co-treated with fisetin] affects the localization of TP53 protein |
affects cotreatment
/ affects localization |
protein |
21216935
|
| C017875 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | [Cisplatin co-treated with fisetin] results in increased expression of TP53 protein |
affects cotreatment
/ increases expression |
protein |
21216935
|
| C017875 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | [Cisplatin co-treated with fisetin] results in increased phosphorylation of TP53 protein |
affects cotreatment
/ increases phosphorylation |
protein |
21216935
|
| C017875 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | fisetin affects the localization of TP53 protein |
affects localization
|
protein |
21216935
|
| C017875 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | fisetin inhibits the reaction [Silicon Dioxide results in increased expression of TP53 mRNA] |
decreases reaction
/ increases expression |
mRNA |
22931364
|
| C017875 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | fisetin results in increased expression of TP53 protein |
increases expression
|
protein |
21216935
|
| C017875 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | SB 203580 inhibits the reaction [[Cisplatin co-treated with fisetin] results in increased phosphorylation of TP53 protein] |
affects cotreatment
/ decreases reaction / increases phosphorylation |
protein |
21216935
|
| C017875 | 54658 |
UGT1A1
BILIQTL1 GNT1 HUG-BR1 UDPGT UDPGT_1-1 UGT1 UGT1A |
UDP glucuronosyltransferase 1 family, polypeptide A1 (EC:2.4.1.17) | UGT1A1 protein results in increased glucuronidation of fisetin |
increases glucuronidation
|
protein |
14557274
|
| C017875 | 54575 |
UGT1A10
UDPGT UGT-1J UGT1-10 UGT1.10 UGT1J |
UDP glucuronosyltransferase 1 family, polypeptide A10 (EC:2.4.1.17) | UGT1A10 protein results in increased glucuronidation of fisetin |
increases glucuronidation
|
protein |
14557274
|
| C017875 | 54577 |
UGT1A7
UDPGT UDPGT_1-7 UGT-1G UGT1-07 UGT1.7 UGT1G |
UDP glucuronosyltransferase 1 family, polypeptide A7 (EC:2.4.1.17) | UGT1A7 protein results in increased glucuronidation of fisetin |
increases glucuronidation
|
protein |
14557274
|
| C017875 | 54576 |
UGT1A8
UDPGT UDPGT_1-8 UGT-1H UGT1-08 UGT1.8 UGT1A8S UGT1H |
UDP glucuronosyltransferase 1 family, polypeptide A8 (EC:2.4.1.17) | UGT1A8 protein results in increased glucuronidation of fisetin |
increases glucuronidation
|
protein |
14557274
|
| C017875 | 54600 |
UGT1A9
HLUGP4 LUGP4 UDPGT UDPGT_1-9 UGT-1I UGT1-09 UGT1-9 UGT1.9 UGT1AI UGT1I |
UDP glucuronosyltransferase 1 family, polypeptide A9 (EC:2.4.1.17) | UGT1A9 protein results in increased glucuronidation of fisetin |
increases glucuronidation
|
protein |
14557274
|
Related Disease
Diseases related to proteins in ChEMBL interactions
OMIM (51)
| OMIM | preferred title | UniProt |
|---|---|---|
| #300438 | 17-beta-hydroxysteroid dehydrogenase x deficiency |
Q99714
|
| #202300 | Adrenocortical carcinoma, hereditary; adcc |
P04637
|
| #300068 | Androgen insensitivity syndrome; ais |
P10275
|
| #312300 | Androgen insensitivity, partial; pais |
P10275
|
| #614740 | Basal cell carcinoma, susceptibility to, 7; bcc7 |
P04637
|
| #613985 | Beta-thalassemia |
P68871
|
| #603902 | Beta-thalassemia, dominant inclusion body type |
P68871
|
| #601816 | Bilirubin, serum level of, quantitative trait locus 1; biliqtl1 |
P22309
|
| #614490 | Blood group, junior system; jr |
Q9UNQ0
|
| #115200 | Cardiomyopathy, dilated, 1a; cmd1a |
P02545
|
| #212112 | Cardiomyopathy, dilated, with hypergonadotropic hypogonadism |
P02545
|
| #605588 | Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 |
P02545
|
| #613641 | Charcot-marie-tooth disease, recessive intermediate b; cmtrib |
Q15046
|
| #114500 | Colorectal cancer; crc |
P18054
|
| #218800 | Crigler-najjar syndrome, type i |
P22309
P22310 |
| #606785 | Crigler-najjar syndrome, type ii |
P22309
P22310 |
| #613916 | Deafness, autosomal recessive 89; dfnb89 |
Q15046
|
| #119900 | Digital clubbing, isolated congenital |
P15428
|
| #181350 | Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 |
P02545
|
| #133239 | Esophageal cancer |
P04637
P18054 |
| #600274 | Frontotemporal dementia; ftd |
P10636
|
| #143500 | Gilbert syndrome |
P22309
P22310 |
| #605130 | Hairy elbows, short stature, facial dysmorphism, and developmental delay |
Q03164
|
| #610140 | Heart-hand syndrome, slovenian type |
P02545
|
| #140700 | Heinz body anemias |
P68871
|
| #176670 | Hutchinson-gilford progeria syndrome; hgps |
P02545
|
| #237900 | Hyperbilirubinemia, transient familial neonatal; hblrtfn |
P22309
|
| #145000 | Hyperparathyroidism 1; hrpt1 |
O00255
|
| #259100 | Hypertrophic osteoarthropathy, primary, autosomal recessive, 1; phoar1 |
P15428
|
| #151623 | Li-fraumeni syndrome 1; lfs1 |
P04637
|
| #151660 | Lipodystrophy, familial partial, type 2; fpld2 |
P02545
|
| #211980 | Lung cancer |
P04637
|
| #248370 | Mandibuloacral dysplasia with type a lipodystrophy; mada |
P02545
|
| #300705 | Mental retardation, x-linked 17; mrx17 |
Q99714
|
| #300220 | Mental retardation, x-linked, syndromic 10; mrxs10 |
Q99714
|
| #131100 | Multiple endocrine neoplasia, type i; men1 |
O00255
|
| #613205 | Muscular dystrophy, congenital, lmna-related |
P02545
|
| #159001 | Muscular dystrophy, limb-girdle, type 1b; lgmd1b |
P02545
|
| #260500 | Papilloma of choroid plexus; cpp |
P04637
|
| #260540 | Parkinson-dementia syndrome |
P10636
|
| #172700 | Pick disease of brain |
P10636
|
| #275210 | Restrictive dermopathy, lethal |
P02545
|
| #180849 | Rubinstein-taybi syndrome 1; rsts1 |
Q92793
|
| #603903 | Sickle cell anemia |
P68871
|
| #313200 | Spinal and bulbar muscular atrophy, x-linked 1; smax1 |
P10275
|
| #275355 | Squamous cell carcinoma, head and neck; hnscc |
P04637
|
| %612223 | Stature quantitative trait locus 11; stqtl11 |
Q00534
|
| #601104 | Supranuclear palsy, progressive, 1; psnp1 |
P10636
|
| #138900 | Uric acid concentration, serum, quantitative trait locus 1; uaqtl1 |
Q9UNQ0
|
| #278300 | Xanthinuria, type i |
P47989
|
| #112100 | Yt blood group antigen |
P22303
|
KEGG DISEASE (73)
| KEGG | disease name | UniProt |
|---|---|---|
| H00033 | Adrenal carcinoma |
O00255
(related)
P04637 (related) |
| H00034 | Carcinoid |
O00255
(related)
|
| H00045 | Malignant islet cell carcinoma |
O00255
(related)
|
| H00246 | Primary hyperparathyroidism |
O00255
(related)
|
| H01102 | Pituitary adenomas |
O00255
(related)
|
| H00264 | Charcot-Marie-Tooth disease (CMT) |
P02545
(related)
Q15046 (related) |
| H00294 | Dilated cardiomyopathy (DCM) |
P02545
(related)
|
| H00420 | Familial partial lipodystrophy (FPL) |
P02545
(related)
|
| H00563 | Emery-Dreifuss muscular dystrophy |
P02545
(related)
|
| H00590 | Congenital muscular dystrophies (CMD/MDC) |
P02545
(related)
|
| H00593 | Limb-girdle muscular dystrophy (LGMD) |
P02545
(related)
|
| H00601 | Hutchinson-Gilford progeria syndrome |
P02545
(related)
|
| H00663 | Restrictive dermopathy |
P02545
(related)
|
| H00665 | Mandibuloacral dysplasia |
P02545
(related)
|
| H01216 | Left ventricular noncompaction (LVNC) |
P02545
(related)
|
| H00599 | 46,XX disorders of sex development (Disorders related to androgen excess) |
P04150
(related)
|
| H00004 | Chronic myeloid leukemia (CML) |
P04637
(related)
|
| H00005 | Chronic lymphocytic leukemia (CLL) |
P04637
(related)
|
| H00006 | Hairy-cell leukemia |
P04637
(related)
|
| H00008 | Burkitt lymphoma |
P04637
(related)
|
| H00009 | Adult T-cell leukemia |
P04637
(related)
|
| H00010 | Multiple myeloma |
P04637
(related)
|
| H00013 | Small cell lung cancer |
P04637
(related)
|
| H00014 | Non-small cell lung cancer |
P04637
(related)
|
| H00015 | Malignant pleural mesothelioma |
P04637
(related)
|
| H00016 | Oral cancer |
P04637
(related)
P04637 (marker) |
| H00017 | Esophageal cancer |
P04637
(related)
P04637 (marker) |
| H00018 | Gastric cancer |
P04637
(related)
|
| H00019 | Pancreatic cancer |
P04637
(related)
P04637 (marker) |
| H00020 | Colorectal cancer |
P04637
(related)
P04637 (marker) P68871 (marker) |
| H00022 | Bladder cancer |
P04637
(related)
P68871 (marker) |
| H00025 | Penile cancer |
P04637
(related)
P04637 (marker) |
| H00026 | Endometrial Cancer |
P04637
(related)
|
| H00027 | Ovarian cancer |
P04637
(related)
|
| H00028 | Choriocarcinoma |
P04637
(related)
|
| H00029 | Vulvar cancer |
P04637
(related)
|
| H00031 | Breast cancer |
P04637
(related)
|
| H00032 | Thyroid cancer |
P04637
(related)
|
| H00036 | Osteosarcoma |
P04637
(related)
P08684 (marker) |
| H00038 | Malignant melanoma |
P04637
(related)
|
| H00039 | Basal cell carcinoma |
P04637
(related)
|
| H00040 | Squamous cell carcinoma |
P04637
(related)
|
| H00041 | Kaposi's sarcoma |
P04637
(related)
|
| H00042 | Glioma |
P04637
(related)
P04637 (marker) |
| H00044 | Cancer of the anal canal |
P04637
(related)
|
| H00046 | Cholangiocarcinoma |
P04637
(related)
|
| H00047 | Gallbladder cancer |
P04637
(related)
|
| H00048 | Hepatocellular carcinoma |
P04637
(related)
|
| H00055 | Laryngeal cancer |
P04637
(related)
P04637 (marker) |
| H00881 | Li-Fraumeni syndrome |
P04637
(related)
|
| H01007 | Choroid plexus papilloma |
P04637
(related)
|
| H00021 | Renal cell carcinoma |
P04637
(marker)
|
| H00093 | Combined immunodeficiencies (CIDs) |
P06239
(related)
|
| H00024 | Prostate cancer |
P10275
(related)
|
| H00062 | Spinal and bulbar muscular atrophy (SBMA) |
P10275
(related)
|
| H00608 | 46,XY disorders of sex development (Disorders in androgen synthesis or action) |
P10275
(related)
|
| H00609 | 46,XY disorders of sex development (Other) |
P10275
(related)
|
| H00058 | Amyotrophic lateral sclerosis (ALS) |
P10636
(related)
|
| H00077 | Progressive supranuclear palsy (PSP) |
P10636
(related)
|
| H00078 | Frontotemporal lobar degeneration (FTLD) |
P10636
(related)
|
| H01205 | Coumarin resistance |
P11712
(related)
|
| H00457 | Primary hypertrophic osteoarthropathy (PHO) |
P15428
(related)
|
| H01246 | Isolated congenital nail clubbing (ICNC) |
P15428
(related)
|
| H00208 | Hyperbilirubinemia |
P22309
(related)
|
| H00192 | Xanthinuria |
P47989
(related)
|
| H00228 | Thalassemia |
P68871
(related)
|
| H00229 | Sickle cell anemia (SCA) |
P68871
(related)
|
| H00001 | Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) |
Q03164
(related)
Q03164 (marker) |
| H00002 | Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia) |
Q03164
(related)
|
| H00504 | Rubinstein-Taybi syndrome |
Q92793
(related)
|
| H00480 | Non-syndromic X-linked mental retardation |
Q99714
(related)
|
| H00658 | Syndromic X-linked mental retardation |
Q99714
(related)
|
| H00925 | 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency |
Q99714
(related)
|